Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ESC Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Trading began Sept. 17 under the symbol "ESCM" on the Nasdaq exchange. The Yokneam, Israel firm's stock previously traded under the symbol "ESCMF." The change reflects the firm's change in Securities and Exchange Act reporting status as of June 23 to comply with broader requirements applicable to U.S. stock issuers versus those of foreign private issuers. Separately, a comprehensive restructuring plan announced Sept. 21 is anticipated to save over $40 mil. annually. The plan, expected to be implemented by April, includes reductions in selling, general and administrative expenses, head count and non-core R&D expenditures, to align the cost structure with revenue capabilities and enhance growth potential. Details of the plan will be released in conjunction with third-quarter financial results later this year

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel